ObsEva SA Stock News

Wedbush analyst Liana Moussatos reiterated a Buy rating on ObsEva SA (OBSV) today and set a price target of $40.00. The company's shares closed last

Wedbush analyst Liana Moussatos reiterated a Buy rating on ObsEva SA (OBSV – Research Report) today and set a price

ObsEva SA (NASDAQ:OBSV) Q4 2019 Earnings Conference Call March 05, 2020 8:00 AM ET Company Participants Mario Corso – Senior Director, Investor Relations Ernest

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In

Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to.

Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and.

Acadian Asset Management LLC bought a new stake in Obseva SA (NASDAQ:OBSV) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 1

Obseva (NASDAQ:OBSV) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, March 5th. Analysts expect Obseva to post earnings of ($0.63) per share for the quar

Obseva SA (NASDAQ:OBSV) has received an average rating of “Hold” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock w

Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved ad

Obseva SA (NASDAQ:OBSV) saw a large growth in short interest in the month of February. As of February 14th, there was short interest totalling 1,470,000 shares, a growth of 33.6% from the January 30th

Geneva, Switzerland and Boston, MA – February 27, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to.

Geneva, Switzerland and Boston, MA – February 18, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and...

Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to.

Obseva SA (NASDAQ:OBSV) – Svb Leerink issued their Q1 2020 earnings estimates for Obseva in a research report issued on Monday, January 27th. Svb Leerink analyst A. Fadia forecasts that the company